Breast cancer remains a devastating scourge for women that just won’t go away.
According to the American Cancer Society, approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer at some point in their lifetime. Every year in the United States, 268,0001 women get the bad news – and 42,0002 die from the disease.
Yet despite this, the x-ray machine doctors use to detect breast cancer, the mammogram, is now 70 years old, first becoming widely used in the 1950s.3
A Painful Ordeal Women Often Desire to Skip
In a regular ordeal that hasn’t changed much in half a century, technicians place women’s breasts in a device that compresses them tightly between metal plates, pinching and pulling on skin, while an x-ray machine takes a two-dimensional image of the breast tissue.
It’s a painful, often excruciating and embarrassing exam that unfortunately still misses a significant number4 of cancerous tumors in the breast.
Yet now, an innovative medical imaging company is developing a revolutionary technology that is a possible game-changer and could potentially improve and even save the lives of thousands of women every year.
The company is Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO), working with an award-winning research team at the University of California, Davis, and other top specialists in the U.S. and Canada, to develop a major advancement in breast imaging technology.
This is a triumph of American ingenuity, and as much as it may change the lives of countless women across the world it could also prove to be a life-changing experience for Izotropic investors.
At Last, a Breast Imaging Technology for the 21st Century!
The izoview platform is unlike any other breast imaging technology currently on the market – and its potential as a platform is far greater than merely that of a diagnostic device.
Instead of women standing in front of an old-fashioned x-ray machine that requires uncomfortable, vice-like breast compression, they lie on a table-top and place their own breast comfortably in a hole in the table.
Beneath the bed-like table, an advanced computed tomography (CT) camera moves around the breast in a 360-degree circle, taking approximately 500 images in just 10 seconds.
Proprietary computer software then takes these 500 raw image-slices of the non-compressed breast and reconstructs the slices into full 3D images of the entire breast.
Comparable to high-resolution MRI Images, But at a Fraction of the Cost
Technological advancements have given the Izoview crystal clear images.
These high-resolution 3D images of the breast are comparable in quality to images created by ultra-expensive Magnetic Resonance Imaging (MRI) scanners – yet for a fraction of the cost.
Four successive working breast CT models have been built and tested at UC Davis Medical Center, each incorporating efficiencies and new cutting-edge technological advancements as they became available. Advancements include breast positioning design, tabletop modifications, positioning aids, x-ray detector and x-ray tube technologies, specialized x-ray beam shaping filters, and many other subtleties that improved the imaging system’s clinical performance and contributed to the current, very high-resolution imaging capability.
The 3D images may allow radiologists to detect cancer tumors not seen by other front-end imaging technologies, as small as 3 to 5mm or about an eighth of an inch.
Researchers estimate that the potential use of izoview could allow doctors to detect breast cancer as much as a year-and-a-half earlier than they normally would with screening mammography, which could allow for earlier treatment.
This is very important. A 2020 study on mortality rates due to delays in cancer treatment found every month that cancer treatment is delayed can raise the risk of death by around 10 percent.5
This could in turn reduce the chance for many women to go through invasive surgeries or full breast removals (mastectomies), which are now performed to save women’s lives. The izoview is being designed for diagnostic use, biopsies and may be used in future for treatment.
The cost savings including the improvement in the lives of hundreds of thousands of women – could be potentially very dramatic.
15 Percent of Mammograms Miss a Tumor
According to one recent study, old-fashioned mammograms miss up to 15 percent6 of cancer tumors and follow-up ultrasounds miss 2.3 percent, often because of dense breast tissue which is common in younger women and in about 40 percent of women over the age of 40.7
Some cancer indicators and or lesions are too small or otherwise undetectable using existing imaging technologies – and early detection of is crucial for surviving many of the 218 different types of breast cancer.
Early Detection Could Mean Fewer Mastectomies
It sometimes happens that a woman will feel a pea-size lump in her breast, have a mammogram and even a follow-up ultrasound test, and be told it is simply a benign cyst. Months or even years later, she will discover that it’s something far more dangerous, a cancerous tumor9 that requires partial or full breast removal.
Approximately 100,00010 women in the U.S. undergo mastectomies every year.
According to one study, fully one third (33 percent) of women diagnosed with early-stage breast cancer have one breast removed and 8.7% have both breasts removed.11
Although breast reconstructive surgery and implants can often mitigate the trauma of mastectomy for some women, the procedure can nevertheless be devastating to women’s personal lives.
Social, marital, work and sexual problems are common.12 A technology that would allow early detection, diagnosis and treatment of breast cancer, and the possible avoidance of mastectomy would be welcomed by millions of women.
Half of Women Will Likely Get a Devastating False Breast Cancer Diagnosis
Yet even more common than false negatives are false positives: False positives are when old-fashioned mammograms reveal abnormalities in the breast tissue that later tests reveal are actually benign cysts and not tumors. About 50 percent of women who get annual mammograms over a ten-year period will have a false positive finding at least once.
The problem is, these false positives cause tremendous stress and worry for thousands of women, their partners and families – and the follow-up imaging exams and biopsies can cost tens of thousands of dollars.
Market for Breast Imaging to Soar to $5.4 Billion by 2025
The market for Izotropic Corporation’s new breast imaging platform is potentially enormous. It’s estimated that the market for breast imaging technology will grow from $3.7 billion in 2020 to $5.4 billion by 202513.
40 million women receive a mammogram each year in the United States. Of these, about 10 percent – or 4 million — are called back for expensive follow-up tests, such as diagnostic mammograms, tomosynthesis, ultrasound, MRI and biopsies.
An advanced breast imaging technology like the izoview could save America’s struggling health care systems billions of dollars – and would be extremely attractive for hospitals and health care managers.
A recent study found that the cost of follow-up imaging and diagnostic procedures after initial mammograms was more than $8 billion annually, just in the United States alone.
Fully Functioning Research Prototypes Now Being Tested
Izotropic Corporation’s breast CT imaging platform could allow radiologists to view 3D images comparable to MRI as part of the initial, low-cost, low-dose routine breast cancer imaging in the future– as many as 40 million per year – and not have to order and then wait for expensive follow-up tests.
Right now, Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO)is the only public company developing an advanced breast CT imaging platform for diagnostic use based clinically validated research prototypes.
U.S. Government Funding and Patents
In addition to investor funds, approximately $20 million in U.S. government grants has been invested to develop this ground-breaking, potentially life-saving technology at the UC Davis Medical Center in Sacramento, California. Izotropic is well-funded to advance important initiatives with news flow expected to be strong in the months ahead.
The researchers developing the izoview platform have 10 unique U.S. patents and patent pending applications, including for using breast CT to measure breast density and to perform robotic guided biopsies.
The patent for biopsies is particularly noteworthy. 71 percent of the 1.6 million breast biopsies performed in the U.S. are found to be negative, at a cost of $2.2 billion.14
A CEO and Scientific Advisory Team Like No Other
CEO, Dr. John McGraw has 21 years’ experience in the healthcare business. He was VP of Operations for Novadaq Technologies Inc. (NASDAQ: NCVQ), a medical device imaging company which was acquired by Stryker Corporation for $700M U.S. in 2017. He was also Senior Vice President Business Development & Strategy for CML HealthCare Inc (TSX: CLC), one of Ontario’s leading providers of laboratory diagnostic services and Canada’s largest provider of medical imaging services which was acquired by LifeLabs (owned by OMERS/Borealis) for $1.3B CAD in 2017.
The principal founder of breast ct technology and director of Izotropic is Dr. John M. Boone, Ph.D., a renowned medical physicist at the University of California, Davis, where he has served for 32 years as a professor of radiology and biomedical engineering and as the principal investigator of the Breast Tomography Project.15 Boone is widely recognized as one of the top medical physicists in the United States.
Former CEO and Special Advisor to Izotropic, Robert Thast, who has enjoyed success with multiple publicly traded companies, has truly assembled an all-star team that provides incredible bench strength behind McGraw and Boone. Scientific and academic advisers include Ph.D and M.D. experts in bioengineering, cancer research, breast imaging, hardware and software development, the FDA approval processes for breast cancer imaging devices and more.
A Low-Priced Stock with Huge Potential
As a publicly traded company only founded in 2016, shares of Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) are currently selling for around a dollar – but likely not for long. The stock was up 455% in 2020 and is expected to garner a lot more attention in 2021.
Only about 40 million shares are outstanding, meaning the current market capitalization is tiny given the “disruptive” nature of Izotropic’s technology and the fact it’s the only publicly traded company developing this kind of platform to address the growing problem of breast cancer.
The company is completing the final design for development of its izoview platform– and is preparing for a clinical study to collect data that it will use for an FDA application for approval of an indication for use as a diagnostic device.
Once FDA approval has been awarded, the company will begin marketing its revolutionary izoview platform to thousands of hospitals and clinics throughout the United States. The company is already participating in the FDA’s Center for Devices & Radiological Health Payor Communication Task Force program, and can use historical trial data in discussions with insurance payers to demonstrate patient benefits for insurance coverage of the company’s new izoview platform.
Hundreds of Millions of Women Will Demand This Technology
Women all over the world will soon hear about a brand-new, easy and dignified way to do breast imaging – lying comfortably for a few seconds on an imaging table rather than standing in front of an x-ray machine while their breasts are compressed between metal plates.
The time to investigate this company is now, before it gains FDA approval – approval for a major breakthrough in breast imaging technology.
4 15% x 40 million mammograms = 6 million. That seems high. 15% of 4 million follow-up exams = 600,000
14 Corporate Presentation, September 2020, p. 10.
15 Ibid., p. 15
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Publisher has not been compensated by any of the profiled companies. The Publisher’s compensation for articles appearing on this website is as follows:
- The Publisher has been paid approximately $500 per week while the advertisement campaign was active by Think Ink Media as compensation to host the article profiling Izotropic Corporation.(“the Company”).
The Publisher has not participated in the creation of the content of any articles appearing on this website and so cannot guarantee the accuracy or completeness of the information in any of the articles. The Publisher expressly disclaims any responsibility or liability for statements made in any of the articles.
SHARE OWNERSHIP. The Publisher does not own any shares of any profiled company and has no information concerning share ownership by others of any profiled company. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES. This website enables users to link to external websites not under the control of The Publisher. The Publisher has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Publisher expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY. The Market Tactic is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind.